Morgan Stanley Benitec Biopharma Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.19 - $0.36 $1,311 - $2,484	-6,900 Reduced 15.16%	38,600 $9,000
Q1 2023 May 15, 2023	SELL	$0.18 - $0.36 $58,216 - $116,432	-323,423 Reduced 87.67%	45,500 $9,000
Q4 2022 Feb 14, 2023	BUY	$0.13 - $5.95 $38,080 - $1.74 Million	292,929 Added 385.46%	368,923 $62,000
Q3 2022 Nov 14, 2022	BUY	$0.31 - $6.32 $21,760 - $443,626	70,194 Added 1210.24%	75,994 $28,000
Q2 2022 Oct 27, 2022	BUY	$0.74 - $2.29 $4,218 - $13,053	5,700 Added 5700.0%	5,800 $7,000
Q2 2022 Aug 15, 2022	BUY	$0.74 - $2.29 $4,218 - $13,053	5,700 Added 5700.0%	5,800 $7,000
Q1 2022 Oct 27, 2022	SELL	$1.96 - $2.96 $11,172 - $16,872	-5,700 Reduced 98.28%	100 $0
Q1 2022 May 13, 2022	BUY	$1.96 - $2.96 $196 - $296	100 New	100 $0

797K

Ticker BNTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,809,500
Market Cap $299M
Description
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.